Real-world safety and efficacy of biologics in elderly patients with psoriasis: A multicenter observational study.
efficiency
elderly patients
infection
psoriasis
safety
Journal
The Journal of dermatology
ISSN: 1346-8138
Titre abrégé: J Dermatol
Pays: England
ID NLM: 7600545
Informations de publication
Date de publication:
19 Jul 2024
19 Jul 2024
Historique:
revised:
18
06
2024
received:
24
04
2024
accepted:
02
07
2024
medline:
20
7
2024
pubmed:
20
7
2024
entrez:
20
7
2024
Statut:
aheadofprint
Résumé
Clinical trials of biologics have frequently excluded elderly patients, resulting in inadequate data on their safety and efficacy. Additionally, evidence of their safety and efficacy remains limited, despite some real-world studies. To assess the safety and efficacy of biologics in elderly patients with psoriasis, we compared these outcomes in younger patients using data from the West Japan Psoriasis Registry (WJPR). The WJPR consists of approximately 30 facilities in Western Japan, including various healthcare settings. This study enrolled 1395 patients who participated in the 2022 follow-up survey of the WJPR and were either using or had used biologics during the survey. These included 456 patients in the elderly group (≥65 years) and 939 patients in the younger group (<65 years). Treatment-ending adverse events (TEAEs) occurred in 15.8% and 11.3% of elderly and younger patients, respectively. The incidence rate per 1000 patient-years (PY) for TEAEs was significantly higher in elderly patients than in younger patients (32.9 vs 23.2, p = 0.0234). Infectious diseases were more prevalent in the elderly group than the younger group; however, no significant difference in the frequency of infectious diseases was found between the two groups (p = 0.0807). Malignant neoplasms occurred significantly more frequently in the elderly group than in the younger group (p = 0.0169). Our results indicate a few concerns about infection when prescribing biologics to elderly patients. Biologics were effective for both elderly and younger patients. We found no significant differences in the proportion of patients with a body surface area score ≤3%, Physician's Global Assessment score 0/1, or Patient's Global Assessment score 0/1, as well as in the mean Dermatology Life Quality Index and the Itch Numerical Rating Scale between the younger and the elderly groups. Overall, our results confirm the appropriateness of using biologics in elderly patients with regard to safety and efficacy.
Identifiants
pubmed: 39031284
doi: 10.1111/1346-8138.17385
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Japanese Dermatological Association.
Références
Parisi R, Iskandar IYK, Kontopantelis E, Augustin M, Griffiths CEM, Ashcroft DM. National, regional, and worldwide epidemiology of psoriasis: systematic analysis and modelling study. BMJ. 2020;369:m1590.
Kubota K, Kamijima Y, Sato T, Ooba N, Koide D, Iizuka H, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5:e006450.
Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the psoriasis longitudinal assessment and registry (PSOLAR). JAMA Dermatol. 2015;151:961–969.
Dobry AS, Quesenberry CP, Ray GT, Geier JL, Asgari MM. Serious infections among a large cohort of subjects with systemically treated psoriasis. J Am Acad Dermatol. 2017;77:838–844.
Nakatani H. Ageing and shrinking population: the looming demographic challenges of super‐aged and super‐low fertility society starting from Asia. Glob Health Med. 2023;5:257–263.
Morishita T, Takemura M, Hayashi M, Saito K, Yamamoto Y, Tsurumi H, et al. Cohort profile: rationale and design of the resource Center for Health Science (RECHS) project – a study of health hazards and medical cost burden among the Japanese population. BMJ Open. 2024;14:e077720.
Kamiya K, Oiso N, Kawada A, Ohtsuki M. Epidemiological survey of the psoriasis patients in the Japanese Society for Psoriasis Research from 2013 to 2018. J Dermatol. 2021;48:864–875.
Medina C, Carretero G, Ferrandiz C, Dauden E, Vanaclocha F, Gómez‐García FJ, et al. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2015;29:858–864.
van Winden MEC, ter Haar ELM, Groenewoud HMM, van de Kerkhof PCM, de Jong E, Lubeek SFK. Disease and treatment characteristics in geriatric psoriasis: a patient survey comparing age groups. Acta Derm Venereol. 2020;100:adv00215.
Osuna CG, García SR, Martín JC, Jiménez VG, López FV, Santos‐Juanes J. Use of biological treatments in elderly patients with skin psoriasis in the real world. Life (Basel). 2021;11:1348.
Shear NH, Betts KA, Soliman AM, Joshi A, Wang Y, Zhao J, et al. Comparative safety and benefit‐risk profile of biologics and oral treatment for moderate‐to‐severe plaque psoriasis: a network meta‐analysis of clinical trial data. J Am Acad Dermatol. 2021;85:572–581.
Kline KA, Bowdish DM. Infection in an aging population. Curr Opin Microbiol. 2016;29:63–67.
Tsuruta N, Imafuku S. Establishment of the Western Japan psoriasis registry and first cross‐sectional analysis of registered patients. J Dermatol. 2021;48:1709–1718.
McLaughlin JM, Khan FL, Thoburn EA, Isturiz RE, Swerdlow DL. Rates of hospitalization for community‐acquired pneumonia among US adults: a systematic review. Vaccine. 2020;38:741–751.
Piaserico S, Conti A, Lo Console F, De Simone C, Prestinari F, Mazzotta A, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94:293–297.
Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol. 2009;27:2758–2765.
Vaengebjerg S, Skov L, Egeberg A, Loft ND. Prevalence, incidence, and risk of cancer in patients with psoriasis and psoriatic arthritis: a systematic review and meta‐analysis. JAMA Dermatol. 2020;156:421–429.
Korber A, Papavassilis C, Bhosekar V, Reinhardt M. Efficacy and safety of Secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. Drugs Aging. 2018;35:135–144.
Tang MM, Chang CC, Chan LC, Heng A. Quality of life and cost of illness in patients with psoriasis in Malaysia: a multicenter study. Int J Dermatol. 2013;52:314–322.
Rencz F, Poor AK, Pentek M, Holló P, Kárpáti S, Gulácsi L, et al. A detailed analysis of ‘not relevant’ responses on the DLQI in psoriasis: potential biases in treatment decisions. J Eur Acad Dermatol Venereol. 2018;32:783–790.
Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L. Comparison of long‐term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol. 2015;172:244–252.
Davila‐Seijo P, Dauden E, Carretero G, Ferrandiz C, Vanaclocha F, Gómez‐García FJ, et al. Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis. J Eur Acad Dermatol Venereol. 2016;30:1942–1950.
Ohata C, Anezaki H, Kaneko S, Okazaki F, Ito K, Matsuzaka Y, et al. Clinical characteristics of patients with psoriasis with family history: a multicenter observational study. J Dermatol. 2023;50:746–752.